Cxbladder was developed by a company whose passion and focus is cancer diagnostics and prognostics to improve patient outcomes.

Clinical publications

  • Breen V, Kasabov N, Kamat AM, et al. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets. BMC Med Res Methodol 2015;15:45. [pdf available]
  • Darling, D., Luxmanan, C., O’Sullivan, P. et al. Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma. Adv Ther 2017. doi:10.1007/s12325-017-0518-7. [pdf available]
  • Holyoake A, O’Sullivan P, Pollock R, et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin Cancer Res 2008;14:742–9. [pdf available]
  • Kavalieris L, O’Sullivan PJ, Frampton C, et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 2017;197:6,1419-1426. [pdf available]
  • Kavalieris L, O’Sullivan PJ, Suttie JM, et al. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. BMC Urol 2015;15:23. [pdf available]
  • Konety, B., Shore, N., Kader, AK. et al. Evaluation of Cxbladder and adjudication of atypical cytology and equivocal cystoscopy. Eur Urol 2019. Article In-Press [pdf available]
  • Lotan Y, Raman JR, Shariat S, et al. The development and clinical validation of a high sensitivity urine biomarker test for the determination of recurrence in urothelial carcinoma patients. American Urological Association Annual Meeting 2016; San Diego, CA, USA. [abstract available]
  • Lotan Y, OʼSullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017; 1–8. [pdf available]
  • Lough T, Luo Q, Luxmanan C, et al. Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis. BMC Urol 2018;18:18. [pdf available]
  • Lough T, Luo Q, O'Sullivan P, et al. Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician–Patient Real-World Clinical Data Analysis. Oncol Ther 2018. [pdf available]
  • O’Sullivan P, Sharples K, Dalphin M, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol 2012; 188:741–7.

To request printed versions of our publications, please contact: